bevacizumab,sintilimab
eli lilly,innovent biologics,etana
['sintilimab', 'orient-31', 'nsclc', 'sclc']
dr. discussing orient-31 study at #esmo22. suggestion of benefit when adding sintilimab (pd1) to chemotherapy over chemotherapy alone in #egfr nsclc, even without vegf blockade. but this is not what we expected based on immunotarget by dr. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him